Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells. [electronic resource]
Producer: 20110818Description: 323-35 p. digitalISSN:- 0394-6320
- Adult
- Anti-Inflammatory Agents -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Blotting, Western
- Case-Control Studies
- Cells, Cultured
- Crohn Disease -- blood
- Endothelial Cells -- enzymology
- Female
- Fibroblast Growth Factor 2 -- metabolism
- Gene Expression Regulation, Enzymologic
- Humans
- Infliximab
- Male
- Nitric Oxide Synthase Type III -- genetics
- Phenotype
- RNA, Messenger -- metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Ribonuclease, Pancreatic -- metabolism
- Serum -- metabolism
- Time Factors
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- Up-Regulation
- Vascular Endothelial Growth Factor A -- metabolism
- Vascular Endothelial Growth Factor Receptor-2 -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.